Telomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board
Telomir also announces Board of Directors departures and additions
TAMPA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc.(Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 to promote longevity in humans and dogs through the treatment of age-related conditions, today announced the passing of Chairman of the Board and Chief Executive Officer Christopher Chapman, Jr., M.D. Out of respect and privacy for Dr. Chapman’s family, details of his passing will not be made available.
Telomir’s Board of Directors has named Erez Aminov, currently Chairman of the Board and Chief Executive Officer of MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA), as a director, Chairman of the Board and Chief Executive Officer of Telomir.
To offer support to Telomir’s new senior management, three Telomir directors have voluntarily resigned from the Telomir Board of Directors, and three individuals have been appointed as replacements. The new Telomir directors are Dr. Matthew P. Del Giudice, Mr. Ned MacPherson and Matthew Pratt Whalen, CPA. Dr. Craig Eagle and Michael Jerman, each sitting directors of Telomir, will remain on the Telomir Board of Directors. The resigning directors are Hugh McColl III, Talhia Tuck and Brad Kroenig.
Dr. Craig Eagle, an independent member of Telomir’s Board of Directors, stated: “The entire Telomir community is devastated by the loss of Dr. Chapman. Not only was he a founding officer and director of Telomir, but he was a leading scientist and researcher as well as a kind and decent man. Our thoughts and thanks go out to Dr. Chapman’s family. We are also grateful to Erez for joining our company to fill these important roles as Telomir continues to progress its business.”
Mr. Aminov stated, “Dr. Chapman’s passion for the potential of Telomir-1 is inspiring, and I hope to carry on with his work with that same passion. I appreciate the trust that the Telomir board has placed in me at this challenging time. I look forward to working with Telomir and moving its promising drug candidate forward.”
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially promote longevity in humans and dogs through the treatment of age-related conditions. Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents us with an increased chance of contracting a number of degenerative and age-related diseases. Telomir’s goal is to develop and commercialize Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life. The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the appointment of Mr. Aminov to his positions with the Company.
Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 and the aging process and safety of Telomir-1 . These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
For further information, please contact:
Telomir Pharmaceuticals
info@Telomirpharma.com
(813) 864-2558
